Two-way antigenic cross-reactivity between severe acute respiratory syndrome coronavirus (SARS-CoV) and group 1 animal CoVs is mediated through an antigenic site in the n-terminal region of the SARS-CoV nucleoprotein

被引:35
|
作者
Vlasova, Anastasia N. [1 ]
Zhang, Xinsheng [1 ]
Hasoksuz, Mustafa [2 ]
Nagesha, Hadya S. [1 ]
Haynes, Lia M. [3 ]
Fang, Ying [4 ]
Lu, Shan [5 ]
Saif, Linda J. [1 ]
机构
[1] Ohio State Univ, Ohio Agr Res & Dev Ctr, Dept Vet Prevent Med, Food Anim Hlth Res Program, Wooster, OH 44691 USA
[2] Istanbul Univ, Fac Vet Med, Dept Virol, TR-34320 Istanbul, Turkey
[3] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA
[4] S Dakota State Univ, Dept Vet Sci, Ctr Infect Dis Res & Vaccinol, Brookings, SD 57007 USA
[5] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA
关键词
D O I
10.1128/JVI.01169-07
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In 2002, severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged in humans, causing a global epidemic. By phylogenetic analysis, SARS-CoV is distinct from known CoVs and most closely related to group 2 CoVs. However, no antigenic cross-reactivity between SARS-CoV and known CoVs was conclusively and consistently demonstrated except for group 1 animal CoVs. We analyzed this cross-reactivity by an enzyme-linked immunosorbent assay (ELISA) and Western blot analysis using specific antisera to animal CoVs and SARS-CoV and SARS patient convalescent-phase or negative sera. Moderate two-way cross-reactivity between SARS-CoV and porcine CoVs (transmissible gastroenteritis CoV [TGEVI and porcine respiratory CoV [PRCV]) was mediated through the N but not the spike protein, whereas weaker cross-reactivity occurred with feline (feline infectious peritonitis virus) and canine CoVs. Using Escherichia coliexpressed recombinant SARS-CoV N protein and fragments, the cross-reactive region was localized between amino acids (aa) 120 to 208. The N-protein fragments comprising as 360 to 412 and as 1 to 213 reacted specifically with SARS convalescent-phase sera but not with negative human sera in ELISA; the fragment comprising as 1 to 213 cross-reacted with antisera to animal CoVs, whereas the fragment comprising as 360 to 412 did not cross-react and could be a potential candidate for SARS diagnosis. Particularly noteworthy, a single substitution at as 120 of PRCV N protein diminished the cross-reactivity. We also demonstrated that the cross-reactivity is not universal for all group 1 CoVs, because HCoV-NL63 did not cross-react with SARS-CoV. One-way cross-reactivity of HCoV-NL63 with group 1 CoVs was localized to as 1 to 39 and at least one other antigenic site in the N-protein C terminus, differing from the cross-reactive region identified in SARS-CoV N protein. The observed cross-reactivity is not a consequence of a higher level of amino acid identity between SARS-CoV and porcine CoV nucleoproteins, because sequence comparisons indicated that SARS-CoV N protein has amino acid identity similar to that of infectious bronchitis virus N protein and shares a higher level of identity with bovine CoV N protein within the cross-reactive region. The TGEV and SARS-CoV N proteins are RNA chaperons with long disordered regions. We speculate that during natural infection, antibodies target similar short antigenic sites within the N proteins of SARS-CoV and porcine group 1 CoVs that are exposed to an immune response. Identification of the cross-reactive and non-cross-reactive N-protein
引用
收藏
页码:13365 / 13377
页数:13
相关论文
共 12 条
  • [1] Potential Antigenic Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses
    Lustig, Yaniv
    Keler, Shlomit
    Kolodny, Rachel
    Ben-Tal, Nir
    Atias-Varon, Danit
    Shlush, Ekaterina
    Gerlic, Motti
    Munitz, Ariel
    Doolman, Ram
    Asraf, Keren
    Shlush, Liran, I
    Vivante, Asaf
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (07) : E2444 - E2449
  • [2] Antigenic cross-reactivity between the nucleocapsid protein of severe acute respiratory syndrome (SARS) coronavirus and polyclonal antisera of antigenic group I animal coronaviruses: Implication for SARS diagnosis
    Sun, ZF
    Meng, XJ
    JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (05) : 2351 - 2352
  • [3] Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry
    Simmons, G
    Reeves, JD
    Rennekamp, AJ
    Amberg, SM
    Piefer, AJ
    Bates, P
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (12) : 4240 - 4245
  • [4] The human severe acute respiratory syndrome coronavirus (SARS-CoV) 8b protein is distinct from its counterpart in animal SARS-CoV and down-regulates the expression of the envelope protein in infected cells
    Keng, Choong-Tat
    Choi, Yook-Wah
    Welkers, Matthijs R. A.
    Chan, Daphne Z. L.
    Shen, Shuo
    Lim, Seng Gee
    Hong, Wanjin
    Tan, Yee-Joo
    VIROLOGY, 2006, 354 (01) : 132 - 142
  • [5] Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV
    Liu, Ye V.
    Massare, Michael J.
    Barnard, Dale L.
    Kort, Thomas
    Nathan, Margret
    Wang, Lei
    Smith, Gale
    VACCINE, 2011, 29 (38) : 6606 - 6613
  • [6] An efficient RNA-cleaving DNA enzyme can specifically target the 5′-untranslated region of severe acute respiratory syndrome associated coronavirus (SARS-CoV)
    Wu, Shuwen
    Xu, Junqiang
    Liu, Jiangxia
    Yan, Xuan
    Zhu, Xiaodong
    Xiao, Gengfu
    Sun, Lunquan
    Tien, Po
    JOURNAL OF GENE MEDICINE, 2007, 9 (12): : 1080 - 1086
  • [7] Exploring the viability of Zeatin as a prospective therapeutic candidate for investigating the complex interplay between severe acute respiratory syndrome coronavirus (SARS-CoV) and Alzheimer’s disease
    A. S. Sriranjini
    Ashish Thapliyal
    Kumud Pant
    In Silico Pharmacology, 12 (1)
  • [8] False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid-based Western blot assay were rectified by the use of two subunits (S1 and S2) of spike for detection of antibody to SARS-CoV
    Maache, M
    Komurian-Pradel, F
    Rajoharison, A
    Perret, M
    Berland, JL
    Pouzol, S
    Bagnaud, A
    Duverger, B
    Xu, JG
    Osuna, A
    Paranhos-Baccalà, G
    CLINICAL AND VACCINE IMMUNOLOGY, 2006, 13 (03) : 409 - 414
  • [9] Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV)
    Lai, SC
    Chong, PCS
    Yeh, CT
    Liu, LSJ
    Jan, JT
    Chi, HY
    Liu, HW
    Chen, A
    Wang, YC
    JOURNAL OF BIOMEDICAL SCIENCE, 2005, 12 (05) : 711 - 727
  • [10] High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa
    Tso, For Yue
    Lidenge, Salum J.
    Pena, Phoebe B.
    Clegg, Ashley A.
    Ngowi, John R.
    Mwaiselage, Julius
    Ngalamika, Owen
    Julius, Peter
    West, John T.
    Wood, Charles
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 102 : 577 - 583